J. Wouter Jukema

The mortality benefit seen with the newer more potent oral P2Y(12) inhibitors prasugrel and ticagrelor over clopidogrel is dependent on the underlying risk: A class effect as suggested by a meta-regression analysis

2018 | Third Faculty of Medicine

Publication